Table 1.

Characteristics of patients who received WT1-TCR-gene transduced lymphocyte transfer

Cohort, patient IDAge (y)SexNumber of T cells infused, per dose (×108)Disease*KaryotypePrior therapyDisease characteristics before TCR-T cell transfer
1        
 TCR-WT-02-M01 68 Male 2 MDS, RCMD 46, XY None Erythroblastosis, blood transfusion dependency 
 TCR-WT-03-M02 65 Female 2 AML/MRC Multiple abnormalities Cytarabine/aclarubicin/G-CSF 30% blasts in BM 
 TCR-WT-06-E03 69 Male 2 MDS, RAEB-1 46, XY None AML/MRC, 24.8% blasts in BM 
2        
 TCR-WT-07-M03 71 Male 10 MDS, REAB 46, XY Azacitidine 10% blasts in BM 
 TCR-WT-08-N04 70 Male 10 MDS, REAB-2 Multiple abnormalities Azacitidine AML/MRC, 40.5% blast in BM 
Extracohort        
 TCR-WT-09-N05† 76 Male 9.7 AML/MRC 46,XY, t(4;21)(q21;q22), add (7)(q22), add(14)(q24) Azacitidine, cytarabine/aclarubicin/G-CSF 87% blasts in BM 
5.6 
 TCR-WT-10-F02 68 Male 6.5 MDS, RCMD 46, XY, del(20)(q1?) None Blood transfusion dependency 
2        
 TCR-WT-11-E04 64 Male 10 MDS, RAEB-1 46, XY None AML/MRC, 24.8% blasts in BM 
Cohort, patient IDAge (y)SexNumber of T cells infused, per dose (×108)Disease*KaryotypePrior therapyDisease characteristics before TCR-T cell transfer
1        
 TCR-WT-02-M01 68 Male 2 MDS, RCMD 46, XY None Erythroblastosis, blood transfusion dependency 
 TCR-WT-03-M02 65 Female 2 AML/MRC Multiple abnormalities Cytarabine/aclarubicin/G-CSF 30% blasts in BM 
 TCR-WT-06-E03 69 Male 2 MDS, RAEB-1 46, XY None AML/MRC, 24.8% blasts in BM 
2        
 TCR-WT-07-M03 71 Male 10 MDS, REAB 46, XY Azacitidine 10% blasts in BM 
 TCR-WT-08-N04 70 Male 10 MDS, REAB-2 Multiple abnormalities Azacitidine AML/MRC, 40.5% blast in BM 
Extracohort        
 TCR-WT-09-N05† 76 Male 9.7 AML/MRC 46,XY, t(4;21)(q21;q22), add (7)(q22), add(14)(q24) Azacitidine, cytarabine/aclarubicin/G-CSF 87% blasts in BM 
5.6 
 TCR-WT-10-F02 68 Male 6.5 MDS, RCMD 46, XY, del(20)(q1?) None Blood transfusion dependency 
2        
 TCR-WT-11-E04 64 Male 10 MDS, RAEB-1 46, XY None AML/MRC, 24.8% blasts in BM 

MDS subtypes were classified by World Health Organization (WHO) criteria.

BM, bone marrow; G-CSF, granulocyte colony-stimulating factor; MRC, myelodysplasia-related changes; RCMD, refractory cytopenia with multilineage dysplasia; REAB, refractory anemia with excess of blasts.

*

At clinical trial entry, classified by WHO criteria.

†

TCR-gene transduced T cells for the first and the second infusion were separately prepared.

View Large